Get the Stockscreener App
510.04
4.64%
-24.82
Madrigal Pharmaceuticals Inc stock is traded at $510.04, with a volume of 379.18K.
It is down -4.64% in the last 24 hours and down -1.87% over the past month.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
See More
Previous Close:
$534.86
Open:
$535
24h Volume:
379.18K
Relative Volume:
1.08
Market Cap:
$11.76B
Revenue:
$1.13B
Net Income/Loss:
$-309.44M
P/E Ratio:
-39.85
EPS:
-12.8001
Net Cash Flow:
$-275.41M
1W Performance:
-0.72%
1M Performance:
-1.87%
6M Performance:
+4.25%
1Y Performance:
+70.26%
1-Day Range:
$510.00
$541.57
1-Week Range:
$497.23
$559.00
52-Week Range:
$265.00
$615.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Name
Madrigal Pharmaceuticals Inc
Sector
Industry
Phone
404-380-9263
Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
510.04 | 11.76B | 1.13B | -309.44M | -275.41M | -12.80 |
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 109.09B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
714.89 | 74.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.17 | 48.64B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.05 | 39.39B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
312.12 | 32.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Initiated | Barclays | Overweight |
| Jan-06-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Nov-05-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-03-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Oct-15-25 | Initiated | Truist | Buy |
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| Feb-28-25 | Upgrade | B. Riley Securities | Neutral → Buy |
| Feb-27-25 | Reiterated | H.C. Wainwright | Buy |
| Jun-28-24 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Apr-22-24 | Initiated | BofA Securities | Underperform |
| Mar-15-24 | Upgrade | B. Riley Securities | Sell → Neutral |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Feb-26-24 | Downgrade | B. Riley Securities | Neutral → Sell |
| Dec-20-22 | Reiterated | Oppenheimer | Outperform |
| Dec-19-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-22 | Reiterated | Piper Sandler | Overweight |
| Dec-19-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-08-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| May-20-21 | Resumed | Goldman | Buy |
| Nov-24-20 | Resumed | Evercore ISI | Outperform |
| Nov-06-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-05-20 | Initiated | BMO Capital Markets | Market Perform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-20 | Initiated | Canaccord Genuity | Buy |
| Jan-09-20 | Upgrade | UBS | Neutral → Buy |
| Nov-07-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-19 | Initiated | Stifel | Hold |
| Jun-10-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Feb-28-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Jan-23-19 | Initiated | UBS | Neutral |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Dec-12-18 | Initiated | B. Riley FBR | Neutral |
| Nov-19-18 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Nov-16-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Sep-04-18 | Initiated | Citigroup | Buy |
| Aug-06-18 | Downgrade | Goldman | Buy → Neutral |
| Jun-28-18 | Initiated | Raymond James | Mkt Perform |
View All
Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News
Madrigal Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:MDGL) 2026-05-09 - Seeking Alpha
Madrigal Pharmaceuticals (MDGL) Quarterly Loss Of US$94 Million Tests Bullish Margin Turnaround Narrative - Sahm
MDGL Maintained by Canaccord Genuity -- Price Target Lowered to $578 - GuruFocus
Madrigal (MDGL) Reports Strong Q1 Revenue and Positive Market Ou - GuruFocus
MDGL Maintains Rating by Evercore ISI Group -- Price Target Lowe - GuruFocus
47 new Madrigal hires get stock awards; options priced at $513.72 - Stock Titan
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up - Yahoo Finance
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2026 Earnings Call Transcript - Insider Monkey
Madrigal Q1 2026 slides: blockbuster Rezdiffra tops $1.1B in sales - Investing.com Australia
Madrigal outlays $1bn for Arrowhead’s siRNA MASH asset - MSN
Madrigal: Q1 Earnings Snapshot - theheraldreview.com
MSN Money - MSN
Madrigal sees 2026 gross-to-net in the mid- to high 30s while advancing F4c outcomes readout expected in 2027 - MSN
Madrigal Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance
Madrigal Pharmaceuticals Q1 2026 Financial Results and Forward-Looking Statements – Rezdiffra Commercialization and Regulatory Updates - Minichart
Madrigal Pharmaceuticals Releases Q1 2026 Financial Results - AlphaStreet
Madrigal Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat
Madrigal Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Madrigal Pharmaceuticals Reports Blockbuster Rezdiffra Sales and Pipeline Expansion in Q1 2026 Financial Results - Minichart
Madrigal Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Madrigal’s (MDGL) MASH Strategy Reiinforced By Rezdiffra Sales Growth and Pipeline Expansion - Yahoo Finance
Madrigal Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Pharma M&A Roundup: Bayer to Acquire Perfuse Therapeutics, Madrigal Enters Licensing Agreement for ARO-PNPLA3 - Pharmaceutical Executive
Earnings call transcript: Madrigal Pharmaceuticals Q1 2026 surprises with earnings beat - Investing.com
Full Transcript: Madrigal Pharmaceuticals Q1 2026 Earnings Call - Benzinga
Madrigal Pharmaceuticals (NASDAQ: MDGL) grows Rezdiffra revenue but remains loss-making - Stock Titan
Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Dip Despite Q1 2026 Earnings Beat and 127% Rezdiffra Revenue Growth - ChartMill
Madrigal (MDGL) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance Singapore
Q1 2026 Madrigal Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
MADRIGAL PHARMACEUTICALS ($MDGL) Releases Q1 2026 Earnings - Quiver Quantitative
Earnings Flash (MDGL) Madrigal Pharmaceuticals Posts Q1 Net Loss $3.25 a Share, Vs. FactSet Est of $4.23 Loss - Moomoo
Madrigal Pharmaceuticals, Inc. announced that its drug interaction study for Ervogastat/Resmetirom is progressing steadily and is expected to officially launch in the fourth quarter of 2026. - Bitget
42,250 patients use Rezdiffra as Madrigal adds MASH gene drug - Stock Titan
Madrigal Pharmaceuticals, Inc. Announces Board Changes, Effective April 22, 2026 - marketscreener.com
Rezdiffra powers Madrigal Pharmaceuticals (NASDAQ: MDGL) to 127% Q1 revenue growth - Stock Titan
BRIEF-Madrigal Pharmaceuticals Q1 Product Revenue USD 311.337 Million - TradingView
Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates - GlobeNewswire
Arrowhead and Madrigal sign global licence for MASH RNAi therapy - Yahoo Finance
Madrigal doubles down on MASH with second licensing deal - BioXconomy
Madrigal Expands MASH Franchise With Precision RNAi License For ARO PNPLA3 - simplywall.st
Should Madrigal’s ARO-PNPLA3 License Deal Reshape the MASH Strategy for Madrigal Pharmaceuticals (MDGL) Investors? - Yahoo Finance
Madrigal Pharmaceuticals Q1 2026 earnings preview - MSN
Madrigal Pharma Adds Another Genetic Medicine to Its Drug Combo Strategy in MASH - MedCity News
Madrigal earnings on deck: Can Rezdiffra sustain blockbuster pace? - Investing.com
Madrigal expands MASH pipeline in potential $1B Arrowhead deal - BioWorld News
Madrigal picks up another siRNA asset for MASH, betting up to $1B with Arrowhead - BioSpace
Madrigal Pharmaceuticals Inc announces exclusive global license for Aro-Pnpla3 from Arrowhead - marketscreener.com
Arrowhead licenses MASH drug candidate to Madrigal for $1B By Investing.com - Investing.com South Africa
Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline - The Manila Times
Biotechnology company Arrowhead Pharmaceuticals announces a major collaboration agreement with Madrigal Pharmaceuticals. - Bitget
Madrigal Pharmaceuticals (MDGL) Stock Analysis: Exploring a 31% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Madrigal Pharmaceuticals Inc Stock (MDGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
11.97%
3.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):